Is the 25-year hepatitis C marathon coming to an end to declare victory?

Table 3 American Association for the Study of Liver Diseases/Infectious Diseases Society of America Guideline Recommendations: Genotypes 1, 2, 3, 4, 5 and 6 hepatitis C virus[58]

HCV genotype	Cirrhosis	Prior Tx	Recommended regimen	Alternative regimen	Notes
1a	No		LDV/SOF 12 wk
			DCV + SOF 12 wk
			SMV + SOF 12 wk
			SOF/VEL 12 wk
			GZR/EBR 12 wk		NS5A RAVs absent
				GZR/EBR 16 wk + RBV	NS5A RAVs present
			OBV/PTV/RTV + DSV 12 wk + RBV
1b	No		LDV/SOF 12 wk
			DCV + SOF 12 wk
			SMV + SOF 12 wk
			SOF/VEL 12 wk
			GZR/EBR 12 wk
			OBV/PTV/RTV + DSV 12 wk
1a	Compensated	Naive	LDV/SOF 12 wk
				DCV + SOF 24 wk ± RBV
				SMV + SOF 24 wk ± RBV	No Q80K
			SOF/VEL 12 wk
			GZR/EBR 12 wk		NS5A RAVs absent
				GZR/EBR 16 wk + RBV	NS5A RAVs present
				OBV/PTV/RTV + DSV 24 wk +RBV
1a	Compensated	PR exp	LDV/SOF 12 wk + RBV or 24 wk
				DCV + SOF 24 wk ± RBV
				SMV + SOF 24 wk ± RBV	No Q80K
			SOF/VEL 12 wk
			GZR/EBR 12 wk		NS5A RAVs absent
				GZR/EBR 16 wk + RBV	NS5A RAVs present
				OBV/PTV/RTV + DSV 24 wk + RBV
1b	Compensated	Naive	LDV/SOF 12 wk
				DCV + SOF 24 wk ± RBV
				SMV + SOF 24 wk ± RBV
			SOF/VEL 12 wk
			GZR/EBR 12 wk
			OBV/PTV/RTV + DSV 12 wk
1b	Compensated	PR exp	LDV/SOF 12 wk + RBV or 24 wk
				DCV + SOF 24 wk ± RBV
				SMV + SOF 24 wk ±- RBV
			SOF/VEL 12 wk
			GZR/EBR 12 wk
			OBV/PTV/RTV + DSV 12 wk
1a or 1b	Decompensated	Naive or exp	SOF/VEL 12 wk + RBV		Child-Pugh
					B or C
2	No	Naive	SOF/VEL 12 wk
				SOF + DCV 12 wk
2	No	PR exp	SOF/VEL 12 wk
				SOF + DCV 12 wk
2	No	SR exp	DCV + SOF 24 wk ± RBV
			SOF/VEL 12 wk + RBV
2	Compensated	Naive	SOF/VEL 12 wk
				SOF + DCV 16-24 wk
2	Compensated	PR exp	SOF/VEL 12 wk
				SOF + DCV 16-24 wk
2	Compensated	SR exp	DCV + SOF 24 wk ± RBV
			SOF/VEL 12 wk + RBV
2	Decompensated	Naive or exp	SOF/VEL 12 wk + WB RBV		Child-Pugh B or C
			DCV + SOF 12 wk + low initial dose RBV		Child-Pugh B or C
3	No	Naive	SOF + DCV 12 wk
			SOF/VEL 12 wk
3	No	PR exp	SOF + DCV 12 wk
			SOF/VEL 12 wk
3	No	SR exp	DCV + SOF 24 wk + RBV
			SOF/VEL 12 wk + RBV
3	Compensated	Naive	SOF/VEL 12 wk
			SOF + DCV 24 wk ± RBV
3	Compensated	PR exp	SOF/VEL 12 wk + RBV
			SOF + DCV 24 wk + RBV
3	Compensated	SR exp	SOF + DCV 24 wk + RBV
			SOF/VEL 12 wk + RBV
3	Decompensated	Naive or exp	SOF/VEL 12 wk + WB RBV		Child-Pugh B or C
			DCV+ SOF 12 wk + low initial dose RBV		Child-Pugh B or C
4	No cirrhosis or compensated	Naive	SOF/LDV 12 wk
			OBV/PTV/RTV 12 wk + RBV
			GRZ/EBV 12 wk
			SOF/VEL 12 wk
4	No	PR exp	SOF/LDV 12 wk
			OBV/PTV/RTV 12 wk + RBV
			GRZ/EBV 12 wk		Relapse
			GRZ/EBV 16 wk + RBV		Others
			SOF/VEL 12 wk
4	Compensated	PR exp	SOF/LDV 12 wk + RBV	SOF/LDV 24 wk
			OBV/PTV/RTV 12 wk + RBV
			GRZ/EBV 12 wk		Relapse
			GRZ/EBV 16 wk + RBV		Others
			SOF/VEL 12 wk
5 or 6	No cirrhosis or compensated	Naive or PR exp	SOF/LDV 12 wk
			SOF/VEL 12 wk

AASLD: American Association for the Study of Liver Diseases; DCV: Daclatasvir; DSV: Dasabuvir; EBR: Elbasvir; GT: Genotype; GZR: Grazoprevir; LDV: Ledipasvir; OBV: Ombitasvir; PR: Peginterferon/ribavirin; PTV: Paritaprevir; RAV: Resistance associated variant; RBV: Ribavirin; RTV: Ritonavir; SMV: Simeprevir; SOF: Sofosbuvir; VEL: Velpatasvir; WB: Weight-based; SR: Sofosbuvir/ribavirin; exp: Experienced; Tx: Treatment.